TeamDrive
RUS

Russian TB vaccine has successfully completed preclinical studies

05 October 2018

GMP News

Minister of Health of the Russian Federation Veronika Skvortsova announced on the Margins of UN General Assembly.

“In recent years, we have developed a new vaccine against tuberculosis, the results of the preclinical studies were excellent and now the clinical studies of the vaccine are ongoing.”

Mrs. Skvortsova noted that many countries are actively interested in the successful developments in the Russian Federation intended for tuberculosis control.

A high-level meeting was held on Wednesday, co-chaired by Mrs. Skvortsova on the Margins of the 73rd UN General Assembly. The Minister noted that the incidence of tuberculosis in the Russian Federation has decreased by 42% over the past 10 years. According to her, substantial success in combating tuberculosis in the Russian Federation became possible partially due to continuous funding for the programs.

Source


Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more